Renovaro Shares Fall After Merger Setback

Dow Jones

Apr 05

By Josh Beckerman

Renovaro shares declined after the company said it received an email from Predictive Oncology terminating an agreement to be sold to Renovaro.

The stock fell 16% to 39 cents in the regular session Friday. It was up 5% to 41 cents after hours.

"Renovaro's position is that POI must comply with the binding obligations thereunder and enter into an exclusive license agreement as required in each of the binding agreements," the company said. It believes Predictive Oncology is in breach of the binding agreements.

A representative for Predictive Oncology didn't immediately reply to a request for comment.

Renovaro focuses on diagnostics, drug discovery and genetically enhanced cancer therapies.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

April 04, 2025 18:45 ET (22:45 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2525759948"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2525759948\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2525759948?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-05 06:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2525759948","market":"hk","top_or_hot":-1,"title":"Renovaro Shares Fall After Merger Setback","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Renovaro shares declined after the company said it received an email from <a href=\"https://laohu8.com/S/POAI\">Predictive Oncology</a> terminating an agreement to be sold to Renovaro. \n</p>\n<p>\n  The stock fell 16% to 39 cents in the regular session Friday. It was up 5% to 41 cents after hours. \n</p>\n<p>\n  \"Renovaro's position is that POI must comply with the binding obligations thereunder and enter into an exclusive license agreement as required in each of the binding agreements,\" the company said. It believes Predictive Oncology is in breach of the binding agreements. \n</p>\n<p>\n  A representative for Predictive Oncology didn't immediately reply to a request for comment. \n</p>\n<p>\n  Renovaro focuses on diagnostics, drug discovery and genetically enhanced cancer therapies. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 04, 2025 18:45 ET (22:45 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Renovaro Shares Fall After Merger Setback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRenovaro Shares Fall After Merger Setback\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-05 06:45</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Renovaro shares declined after the company said it received an email from <a href=\"https://laohu8.com/S/POAI\">Predictive Oncology</a> terminating an agreement to be sold to Renovaro. \n</p>\n<p>\n  The stock fell 16% to 39 cents in the regular session Friday. It was up 5% to 41 cents after hours. \n</p>\n<p>\n  \"Renovaro's position is that POI must comply with the binding obligations thereunder and enter into an exclusive license agreement as required in each of the binding agreements,\" the company said. It believes Predictive Oncology is in breach of the binding agreements. \n</p>\n<p>\n  A representative for Predictive Oncology didn't immediately reply to a request for comment. \n</p>\n<p>\n  Renovaro focuses on diagnostics, drug discovery and genetically enhanced cancer therapies. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 04, 2025 18:45 ET (22:45 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2525759948","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2525759948","pubTimestamp":1743806700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Renovaro shares declined after the company said it received an email from Predictive Oncology terminating an agreement to be sold to Renovaro.The stock fell 16% to 39 cents in the regular session Friday. It was up 5% to 41 cents after hours.\"Renovaro's position is that POI must comply with the binding obligations thereunder and enter into an exclusive license agreement as required in each of the binding agreements,\" the company said. It believes Predictive Oncology is in breach of the binding agreements.A representative for Predictive Oncology didn't immediately reply to a request for comment.Renovaro focuses on diagnostics, drug discovery and genetically enhanced cancer therapies.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","BK4139":"生物科技","RENB":"Lunai Bioworks","BK4198":"医疗保健用品","POAI":"Predictive Oncology"},"translate_title":"合并受挫后Renovaro股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RENB":0.9,"POAI":0.9},"content_text":"By Josh Beckerman \n\n\n \n\n\n  Renovaro shares declined after the company said it received an email from Predictive Oncology terminating an agreement to be sold to Renovaro. \n\n\n  The stock fell 16% to 39 cents in the regular session Friday. It was up 5% to 41 cents after hours. \n\n\n  \"Renovaro's position is that POI must comply with the binding obligations thereunder and enter into an exclusive license agreement as required in each of the binding agreements,\" the company said. It believes Predictive Oncology is in breach of the binding agreements. \n\n\n  A representative for Predictive Oncology didn't immediately reply to a request for comment. \n\n\n  Renovaro focuses on diagnostics, drug discovery and genetically enhanced cancer therapies. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 04, 2025 18:45 ET (22:45 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}